BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Historical Holders from Q1 2016 to Q3 2025

Symbol
ONC on Nasdaq
Type / Class
Equity / Ordinary shares, par value $0.0001 per share
Shares outstanding
1,385,160,313
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
32,945,982
Holdings value
$11,221,898,831
% of all portfolios
0.003%
Number of holders
258
Number of buys
149
Number of sells
-116
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HHLR ADVISORS, LTD. 4.9% -25.7% $16,788,174,431 -$5,939,951,540 68,551,141 -26.1% HHLR Advisors, Ltd. 09 May 2025

Institutional Holders of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 32,945,982 $11,221,898,831 -$346,904,029 $340.7 258
2025 Q2 34,445,503 $8,338,029,358 -$2,097,913,474 $242.07 240
2025 Q1 42,522,929 $11,571,304,178 -$300,776,021 $272.17 260
2024 Q4 43,668,178 $8,065,581,343 -$576,365,574 $184.71 222
2024 Q3 46,519,526 $10,440,141,817 -$116,771,313 $224.51 221
2024 Q2 46,804,066 $6,679,478,929 +$49,458,709 $142.67 195
2024 Q1 46,433,670 $7,261,664,670 +$228,390,098 $156.39 198
2023 Q4 44,965,141 $8,109,589,388 -$358,939,167 $180.36 201
2023 Q3 46,934,356 $8,443,617,070 -$8,576,628 $179.87 195
2023 Q2 47,044,110 $8,388,424,595 -$134,114,517 $178.3 200
2023 Q1 47,729,619 $10,288,729,347 -$365,549,782 $215.53 214
2022 Q4 49,411,792 $10,871,665,562 -$822,129,900 $219.94 206
2022 Q3 53,491,519 $7,213,600,064 -$18,667,417 $134.82 204
2022 Q2 53,542,991 $8,666,746,485 -$222,094,321 $161.85 217
2022 Q1 54,923,857 $10,369,831,154 -$143,839,726 $188.6 228
2021 Q4 55,475,829 $15,026,076,469 -$242,691,110 $270.93 247
2021 Q3 56,111,399 $20,367,209,544 +$187,897,220 $363 242
2021 Q2 55,478,557 $19,043,602,189 -$143,508,273 $343.19 259
2021 Q1 55,905,428 $19,451,416,879 +$655,221,281 $348.08 241
2020 Q4 54,296,531 $14,026,755,839 -$183,663,940 $258.39 234
2020 Q3 54,822,916 $15,700,067,419 +$1,338,448,467 $286.44 238
2020 Q2 50,121,058 $9,441,745,077 +$213,639,854 $188.4 209
2020 Q1 48,964,204 $6,027,968,489 -$8,363,206 $123.11 205
2019 Q4 48,934,325 $8,110,832,589 -$138,704,780 $165.76 217
2019 Q3 49,991,082 $6,121,591,847 +$324,001,095 $122.46 192
2019 Q2 49,119,839 $6,088,356,127 +$19,061,884 $123.95 196
2019 Q1 46,975,583 $6,199,612,280 +$70,636,203 $132 193
2018 Q4 47,454,252 $6,654,826,169 -$438,071,948 $140.26 188
2018 Q3 45,496,681 $7,835,602,804 +$598,946,530 $172.22 142
2018 Q2 42,212,313 $6,489,342,702 +$892,872,904 $153.73 128
2018 Q1 36,449,398 $6,123,436,880 +$1,501,911,684 $168 122
2017 Q4 27,567,001 $2,693,889,000 +$229,200,708 $97.72 93
2017 Q3 25,192,357 $2,606,391,144 +$502,359,860 $103.46 81
2017 Q2 20,400,002 $917,998,000 +$131,190,803 $45 57
2017 Q1 17,607,585 $644,614,000 +$43,545,126 $36.61 54
2016 Q4 16,604,419 $504,116,000 +$195,354,542 $30.36 54
2016 Q3 10,161,007 $313,122,000 +$58,302,863 $30.81 38
2016 Q2 8,275,591 $241,301,000 +$16,647,965 $29.8 39
2016 Q1 7,721,859 $221,022,000 +$221,022,000 $29.31 40